Basic & Clinical Medicine ›› 2020, Vol. 40 ›› Issue (5): 639-643.

• Original Articles • Previous Articles     Next Articles

Synergistic antitumor effect of Hsp90 targeting-inhibitory peptide P7 combined with docetaxel in lung adenocarcinoma cell line A549

WU You-ming, LIU Na-si, CAO Ming-yue, HUANG Wei, LIU Yan-yong, YANG Nan*   

  1. Department of Pharmacology,Institute of Basic Medical Sciences CAMS,School of Basic Medicine PUMC,Beijing 100005,China
  • Received:2020-02-13 Revised:2020-03-18 Online:2020-05-05 Published:2020-04-30
  • Contact: *yangnan@ibms.pumc.edu.cn

Abstract: Objective To investigate the effects of combination of Hsp90 bifunctional targeting-inhibitory peptide LPLTPLP (P7) with chemotherapy drug docetaxel(DTX) on lung adenocarcinoma cell line A549. Methods DTX and peptide P7 alone or combined were incubated with A549 cell for 48 hours, thereafter the effect of the drug on cell viability was evaluated using the CCK-8 method. Flow cytometry was carried out to quantify apoptotic cells. The expression of apoptotic and drug resistant protein were assessed by Western blot analysis. Results DTX and P7 exhibited a synergistic effect on cell survival. The apoptosis rate of the combined drug group was 25.8%, which was significantly higher than that of DTX group(P<0.05). Apoptosis-related proteins Bcl-2 and PARP were significantly down-regulated(P<0.05), and cleaved-PARP protein was significantly up-regulated(P<0.05). Meanwhile, drug-resistant protein major vault protein(MVP) was significantly down-regulated(P<0.05). Conclusions DTX ombined with targeted peptide P7 can significantly increase the apoptosis rate of A549 cells, which may be related to expression level of Bcl-2, inactivation of DNA repair enzyme PARP and down-regulation of multidrug-resistant protein MVP.

Key words: lung adenocarcinoma, synergy, apoptosis, drug-resistance, heptapeptide

CLC Number: